Recombinant human endostatin (Jiangsu Wuzhong Pharmaceutical)

重组人内皮抑素（江苏吴中医药）

Report date: 2023/08/07 17:45:56

Base Information

Drug NameRecombinant human endostatin (Jiangsu Wuzhong Pharmaceutical)
Drug Alias Name重组人血管内皮抑素注射液苏粒佳DB108
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor receptor antagonists
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Wuzhong Pharmaceutical Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDenovo Biopharma Llc
Inactive CompaniesJiangsu Wuzhong Medicine Group Co Ltd Suzhou Zhongkai Biopharmaceutical FactoryJiangsu Wuzhong Medicine Group Co Ltd Institute Of Biomedicine
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A